EE279 Cost-Effectiveness of T-DM1 vs. Trastuzumab for Adjuvant Treatment in HER2 Early Breast Cancer (eBC) With Residual Disease in Colombia
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.663
https://www.valueinhealthjournal.com/article/S1098-3015(25)03220-6/fulltext
Title :
EE279 Cost-Effectiveness of T-DM1 vs. Trastuzumab for Adjuvant Treatment in HER2 Early Breast Cancer (eBC) With Residual Disease in Colombia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)03220-6&doi=10.1016/j.jval.2025.09.663
First page :
Section Title :
Open access? :
No
Section Order :
10241